FocalTherics (NASDAQ:FOCL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of FocalTherics (NASDAQ:FOCL) to a hold rating in a report released on Saturday.

Other research analysts have also issued reports about the stock. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.00.

FocalTherics Trading Down 2.5%

NASDAQ:FOCL opened at $5.97 on Friday. The company has a market capitalization of $223.76 million, a PE ratio of -7.37 and a beta of -0.04. FocalTherics has a 1-year low of $1.21 and a 1-year high of $6.36. The firm has a fifty day moving average price of $5.26. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $20.48 million for the quarter, compared to the consensus estimate of $19.46 million. FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%. On average, equities analysts predict that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Insider Buying and Selling at FocalTherics

In related news, Director Joshua Levine acquired 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $4.22 per share, with a total value of $42,200.00. Following the completion of the transaction, the director directly owned 35,000 shares of the company’s stock, valued at $147,700. This trade represents a 40.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FOCL. Flax Pond Capital LLC bought a new position in FocalTherics in the 4th quarter valued at about $2,623,000. Rock Springs Capital Management LP lifted its position in FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after acquiring an additional 91,500 shares during the last quarter. Kovack Advisors Inc. bought a new stake in shares of FocalTherics during the fourth quarter worth approximately $53,000. Leonteq Securities AG bought a new stake in shares of FocalTherics during the fourth quarter worth approximately $313,000. Finally, Lido Advisors LLC acquired a new position in shares of FocalTherics in the first quarter valued at approximately $40,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.